A study showed recreational opioid users did not like and were less
prone to snort the company's painkiller, Egalet-001, than MS Contin.
Egalet's study results come a week before a panel of experts
advising the U.S. Food and Drug Administration discuss if
reformulated versions of opioids and other painkillers are less
likely to be abused.
(Reporting by Vidya L Nathan in Bengaluru; Editing by Savio D'Souza)
[© 2015 Thomson Reuters. All rights
reserved.] Copyright 2015 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |